Arbutus Biopharma Corporation
NASDAQ:ABUSBiotechnology
+$0.05 today
- Market cap
- $630.03M
- Beta
- 0.63
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.83
Volume 2.90M
Average 1.76M
ABUS EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Arbutus Biopharma CorporationNASDAQ: ABUS
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $169.72M, compared with -$24.17M a year earlier. Trailing-twelve-month EBITDA was $160.85M.
Context
- EBITDA amounted to 234.6% of revenue in FY2025, down 873.8 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $181.25M (+648.6%) for the fiscal year ending Dec 2026, a step up from the +51.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $169.72M+4653.9% QoQ
- Last fiscal yearDec 2025
- -$33.04M+51.7% YoY
- LTMMar 2026
- $160.85M+305.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +802.4% | -254.7% | -1057.1 pp |
| 1 year | +51.7% | +648.6% | +596.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.04M) USD
- Year-over-year change
- +51.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.04M) | +51.7% |
| FY2024 | 2024-12-31 | (68.4M) | +3.6% |
| FY2023 | 2023-12-31 | (70.99M) | -14.8% |
| FY2022 | 2022-12-31 | (61.86M) | +13.6% |
| FY2021 | 2021-12-31 | (71.64M) | — |
EBITDA vs competitors
How ABUS compares with its peers on the latest reported figures
- ABUS's LTM Mar 2026 EBITDA of $160.85M is the 2nd highest of the 9 companies compared; the peer median is -$65.8M.
- Its year-over-year change of +305.5% is the 2nd highest of 8, against a peer median of +24.4%.
- EBITDA amounts to 84.0% of revenue for ABUS, versus a peer median of 100.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.15B | +773.6% | — | 24.0% | |
| LTM Mar 2026 | $160.85M | +305.5% | — | 84.0% | |
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$53.46M | -44.4% | — | — | |
| LTM Mar 2026 | -$78.13M | — | — | 8478.5% | |
| LTM Mar 2026 | -$179.89M | -30.1% | — | — | |
| LTM Mar 2026 | -$438.52M | +24.4% | — | 669.6% | |
| LTM Sep 2026 | -$603.58M | -466.2% | — | 133.9% | |
| Peer median (excluding ABUS) | -$65.8M | +24.4% | — | 100.6% | |
Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.99M | 39.02M | 18.14M | 6.17M | 14.08M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 363K |
| Gross Profit | 10.99M | 39.02M | 18.14M | 6.17M | 13.72M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Research & Development | 65.5M | 84.41M | 73.7M | 54.04M | 25.24M |
| Selling, General & Admin | 17.14M | 17.83M | 22.48M | 22.11M | 15.89M |
| Operating Expenses | 84.51M | 104.48M | 96.24M | 82.49M | 40.77M |
| Depreciation & Amortization | 1.75M | 1.43M | 1.4M | 1.38M | 363K |
| EBITDA | (71.64M) | (61.86M) | (70.99M) | (68.4M) | (33.04M) |
| EBITDA Margin | -652.0% | -158.5% | -391.3% | -1108.5% | -234.6% |
| Operating Income | (73.52M) | (65.46M) | (78.1M) | (76.32M) | (27.05M) |
| Operating Margin | -669.1% | -167.8% | -430.5% | -1236.7% | -192.1% |
| Interest Income | 127K | 2.19M | 5.69M | 6.59M | 4.07M |
| Interest Expense | 2.86M | 1.73M | 459K | 137K | 97K |
| Other Income / Expenses | (2.73M) | 444K | 5.25M | 6.4M | (6.45M) |
| Income Before Tax | (76.25M) | (65.01M) | (72.85M) | (69.92M) | (33.5M) |
| Pre-Tax Margin | -693.9% | -166.6% | -401.6% | -1133.0% | -237.9% |
| Income Tax Expense | 0 | 4.44M | 0 | 0 | 0 |
| Net Income | (76.25M) | (69.46M) | (72.85M) | (69.92M) | (33.5M) |
| Net Margin | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (Basic) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| EPS (Diluted) | (0.73) | (0.46) | (0.44) | (0.38) | (0.17) |
| Weighted Avg Shares | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
| Weighted Avg Shares (Diluted) | 106.24M | 150.94M | 165.96M | 185.61M | 191.6M |
Arbutus Biopharma Corporation
NASDAQ:ABUS
Intrinsic Alpha fair value
Locked
Current Price
$4.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.